A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
[my_disclaimer]
Depression affects around 1 in 6 adults in the UK at some point, with symptoms including low mood, loss of interest, fatigue, sleep issues, and suicidal thoughts. Standard treatments (antidepressants, CBT, lifestyle changes) help many, but some patients experience limited relief, side effects, or treatment-resistant depression. In 2025, private specialist clinics prescribe CBPMs for depression symptoms when other options have been insufficient, with emerging real-world evidence from UK registries showing benefits for some patients.
This guide covers current evidence, access, product considerations, and risks.
1. Evidence for CBPMs in Depression (2025 Update)
Evidence is emerging and mostly observational — no large-scale RCTs exist specifically for CBPMs in depression.
- Real-World UK Data UK Medical Cannabis Registry and private clinic outcomes show some patients with depression report improvements in mood, sleep, anxiety, and quality of life at 1–6 months. Depression is one of the top mental health indications (after anxiety/PTSD), with positive outcomes in many cases.
- CBD-Focused Evidence CBD shows potential antidepressant effects in preclinical models and small human studies, possibly via serotonin modulation and neuroplasticity. CBD-dominant products are often used for mood and anxiety components of depression.
- THC and Balanced Products Low-dose THC may improve mood and motivation in some patients, but high doses can worsen depression or induce anxiety. Balanced THC/CBD products are more commonly prescribed in UK private practice.
- NHS Position NICE and NHS England do not recommend CBPMs for depression due to insufficient high-quality evidence. NHS access is extremely rare.
- Limitations Data is from patient registries and case series. Long-term safety, optimal dosing, and THC/CBD ratios need more research. Some patients report no benefit or worsening symptoms (e.g., increased anhedonia).
2. Access for Depression in 2025
NHS — Virtually impossible for depression alone (not NICE-approved).
Private Clinics — Realistic path for eligible patients. Eligibility: Diagnosed depression (often treatment-resistant), 2+ conventional treatments tried (e.g., SSRIs/SNRIs, CBT, therapy) with insufficient benefit/side effects, medical records.
Process (Private)
- Self-refer to CQC-regulated clinic (e.g., Releaf, Alternaleaf, Curaleaf Clinic, Mamedica, Lyphe).
- Online eligibility check/upload records.
- Specialist consultation (£50–£200).
- Prescription if suitable (often CBD-dominant or balanced THC/CBD).
- Medication from licensed pharmacy (home delivery).
- Follow-ups (1–3 months).
Costs
- Consultation: £50–£200
- Medication: £50–£300+/month (CBD-dominant often cheaper)
- Follow-ups: £65–£150
3. CBD vs THC for Depression
| Aspect | CBD-Dominant Products | THC-Inclusive Products |
|---|---|---|
| Effects on Depression | May improve mood, reduce anxiety, enhance motivation | Low dose may lift mood; high dose can worsen depression/anxiety |
| Common Forms | Oils, capsules, broad-spectrum (0% THC) | Balanced THC/CBD oils, capsules |
| Evidence | Preliminary positive for mood/anxiety | Mixed; real-world reports vary |
| Risks | Lower (fatigue rare) | Higher (dependence, psychiatric effects) |
| UK Private Use | Often first-line for mood/anxiety components | Used cautiously when CBD alone insufficient |
Clinics typically start with CBD-dominant/low-THC due to lower risk profile.
4. Risks and Side Effects
- Common: Dry mouth, fatigue, appetite changes
- THC-related: Potential worsening of depression/anxiety (high doses), dependence, cognitive effects, driving risks (DVLA strict)
- General: Interactions with antidepressants, psychiatric effects in vulnerable people
- Long-term: Limited data; potential for tolerance or worsening symptoms in some
Specialists monitor closely and start low/slow.
5. Legal & Practical Notes
- CBPMs are prescription-only (Schedule 2).
- Possession without prescription illegal (Class B).
- Driving: Impairment windows apply — check DVLA.
- No NHS funding for depression — full private cost.
Sources
- UK Medical Cannabis Registry patient outcomes
- NICE guidelines on CBPMs
- GMC specialist prescribing rules
- Real-world studies on cannabinoids and depression (2023–2025)
- Clinic data (Releaf, Alternaleaf, Curaleaf)